Gabapentin and tiagabine for social anxiety: A randomized, double-blind, crossover study of 8 adults

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 11, Issue 3, 2009, Pages 123-

  Urbano, Maria R ^a   Spiegel, David R ^a   Laguerta, Nena ^a   Shrader, Catherine J ^a   Rowe, Daniel F ^a   Hategan, Liana F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84555178570     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.08l00641     Document Type: Letter

References (10)

1. Mathew SJ, Ho S. Etiology and neurobiology of social anxiety disorder. J Clin Psychiatry 2006;67(suppl 12):9-13
2. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry 2006;67(suppl 12): 20-26
3. Keller MB. Social anxiety disorder clinical course and outcome: review of Harvard/Brown Anxiety Research Project (HARP) findings. J Clin Psychiatry 2006;67(suppl 12):14-19
4. Crane D. Tiagabine for the treatment of anxiety. Depress Anxiety 2003;18(1):51-52
5. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003;64(10):1245-1249
6. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20(4):467-471
7. Maneuf YP, Gonzalez MI, Sutton KS, et al. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci 2003;60(4):742-750
8. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-173
9. Heimberg RG, Holaway RM. Examination of the known-groups validity of the Liebowitz Social Anxiety Scale. Depress Anxiety 2007;24(7):447-454
10. Sanjatovic M, Ramirez L. Rating Scales in Mental Health. 2nd ed. Cleveland, Ohio: Lexi-Comp; 2003